Bladder cancer
Patients with moderate to severe bladder cancer frequently receive intravenous immunotherapy utilizing a weakened and live strain of bacillus Calmette-Guerin (BCG). BCG is one of the first immunotherapy treatments approved by the FDA, and it is extraordinarily effective at preventing the recurrence of bladder cancer. BCG stimulates the immune system to generate an immune response that targets both bacteria and adjacent bladder cancer cells. Nearly 70% of patients with bladder cancer who receive BCG immunotherapy enter remission.
